PCSK9 inhibitors, with substantial clinical success. High triglyceride levels have also been associated with increased risk of CAD, but initial results of treatments to block tri glyceride synthesis, such as niacin and fibrate derivatives, have not yielded improvements in clinical outcomes. Variants in genes that encode proteins regulating the metabolism of triglyceriderich lipoproteins, such as in ANGPTL3, have been found to modulate CAD risk 1 and have, therefore, emerged as possible therapeutic targets. Chadwick and colleagues now report the use of genome base editing to generate lossoffunction Angptl3 mutations in mice and thereby lower blood lipid levels 2 .
Triglycerides and other lipids circulate in the blood in the form of lipoprotein particles. By inhibiting lipoprotein lipase, angiopoietin related protein 3 (ANGPTL3) regulates metabolism of these lipoproteins and subse quently alters blood lipid levels (FIG. 1) . In 2002, Koishi and colleagues first reported significant hypolipidaemia in ANGPTL3deficient mice 3 . Later, Musunuru and coworkers described a family whose members were affected by combined hypolipidaemia due to compound LDLR knockout (homozygous or composite heterozygous) also responded positively to the antibody treatment, demonstrating its poten tial to treat those who are otherwise resistant to currently available therapies. These two thera pies are also being investigated in multiple cohorts of patients with dyslipidaemia.
Another emerging approach to inhibit ANGPTL3 is via in vivo gene editing to induce permanent lossoffunction ANGPTL3 muta tions. Since its discovery in 2012, CRISPRCas9 technology has garnered great excite ment for its capacity to introduce speci fic mutations at a desired location in the genome 7 . However, potential undesired on target mutagenesis from DNA double strand breaks, offtarget mutagenesis from insuffi cient specificity of the guide RNA, and inefficient ontarget mutagenesis due to low rate homologydirected repair have combined to prevent effective in vivo genome editing 8 . To circumvent these problems, researchers have developed a novel CRISPRderived method to edit a gene sequence without inducing DNA doublestrand breaks 9 . Known as a base editor, the system is composed of Cas9 nickase and guide RNA, to target a speci fic gene locus, and a cytidine deamin ase, to convert cytosine to uracil at a particu lar position in the free DNA strand. Cells then repair and replicate the DNA using a uracilcontaining strand as a backbone, ulti mately changing a cytosine to a thymine at a precise location. This capacity to alter the DNA sequence without cleaving its strands enables more precise and predictable gene editing by substantially lowering undesired indels at the site of doublestrand breaks.
Using the thirdgeneration base editor (BE3) delivered via adenoviral vectors, Chadwick and colleagues now report success ful generation of lossoffunction Angptl3 mutations in mice 2 . The investigators first injected BE3 without guide RNA (BE3 control) or BE3 with Angptl3targeting guide RNA (BE3Angptl3) into healthy mice. After 1 week, deep sequencing of Angptl3 target sites in liver tissue, the primary organ produ cing ANGPTL3, showed highly efficient genome editing with a median rate of 35% and virtually no offtarget mutagenesis. In addition, blood levels of triglycerides and total cholesterol were significantly reduced in the BE3 Angptl3 group compared with the control group. heterozygous nonsense lossoffunction ANGPTL3 mutations 4 . These family members had markedly reduced levels of both triglycer ides and LDL, two important drivers of CAD risk, without evidence of coronary athero sclerotic plaques. These findings were further corroborated by a populationbased study that demonstrated significantly decreased risk of CAD among heterozygous carriers of lossoffunction ANGPTL3 mutations. Given its distinct function primarily target ing triglyceriderich lipoproteins, ANGPTL3 is poised to be a novel drug target providing additional or synergistic therapeutic efficacy beyond LDLlowering therapies. Two ANGPTL3 inhibition therapies, an antisense oligonucleotide targeting ANGPTL3 mRNA and a human mono clonal antibody against ANGPTL3, are now in phase I-II clinical trials 5, 6 , and the results so far are encouraging. Both treatments were well tolerated, decreasing the levels of various plasma lipid fractions, such as LDL and tri glycerides. Notably, a small subset of patients with marked familial hyperlipidaemia due to Another emerging approach to inhibit ANGPTL3 is via in vivo gene editing...
Similar treatment effects were also observed in Ldlr
−/− mice, consistent with previous observations. BE3Angptl3, BE3 target ing Pcsk9 alone, and BE3 targeting a combin ation of Angptl3 and Pcsk9 were associated with similar reductions in total cholesterol levels, with no evidence that the combination approach was superior. Overall, the study by Chadwick and colleagues success fully demon strates the feasibility of safely and effectively introducing lossoffunction mutations in dyslipidaemiaassociated genes in vivo, with significant lipidlowering effects.
Several aspects make ANGPTL3 an attrac tive target for the BE3 therapy. First, ANGPTL3 is primarily synthesized in the liver. The liver is an ideal organ for in vivo genome editing because of its proliferative potential as well as tissue accessibility by intravenous treatments. Second, the complete knockout of ANGPTL3, a possible outcome of genome editing, has been shown to be safe based on both mouse and human data. Lastly, ANGPTL3 inhib ition requires the introduc tion of inactiv ating mutations, which is tech nically easier than precisely introducing a specific gene mutation.
Although the study demonstrated similar cholesterolreducing effects of an ANGPTL3 targeted therapy and a PCSK9targeted ther apy, the effectiveness in preventing CAD remains to be determined given their distinct cholesterolreducing profiles. ANGPTL3 targeted therapy is a more potent triglyceride lowering therapy, whereas PCSK9targeted therapy is a more potent LDLlowering ther apy. Interestingly, inhibiting both ANGPTL3 and PCSK9 did not result in any synergistic or additive effects. This observation might partly be due to interspecies differences in the way in which cholesterol is metabolized. Also, a combin ation of halved equal doses of BEAngptl3 and BEPcsk9 might not be an adequate dosage. The combined ther apy might also have more dynamic effects in dyslipidaemic states, as indicated by possible changes in how these treatments might affect other lipid fractions (such as LDL) and metabolic markers. Although this study did not establish comparative efficacies of Angptl3targeted therapy versus PCSK9 inhibitors or other cholesterol lowering therapies, these findings demonstrate great promise for lowering blood cholesterol and triglyceride levels.
Will in vivo genome editing provide a potential curative strategy for CAD in humans? A primary benefit of genome edit ing lies in its capacity to achieve reliable and dur able therapeutic effects by permanently modify ing genes of interest, removing the need for repeated administration of drugs. Given that medication nonadherence and variable therapeutic response to conven tional therapies are major hurdles in caring for patients with dyslipidaemia, genome edit ing might provide an attractive, lifelong solu tion especially for those with a severe form of familial hyperlipidaemia. Before consider ation for possible clinical translation, however, ethical and regulatory challenges as well as multiple hurdles must be overcome. First, continuing concerns about the risk of off target mutagenesis and unintended ontarget mutagenesis must be addressed, because these treatments cause irreversible genetic changes with possible serious adverse effects. Second, preliminary findings indicate that ongoing exposure to Cas9 might cause undesired immunological adverse effects or treatment failure, preventing possible future use 10 . Third, the use of viral vectors can cause potentially lifethreatening reactions and, therefore, other methods of safe delivery should be explored.
In summary, the study by Chadwick and colleagues is a proofofconcept and hypothesis generating study that demon strates the feasibility of in vivo genome editing to induce inactivating mutations in ANGPTL3 
